SCHEMBL4590055

SCHEMBL4590055

CN(C)CCCCNC(=O)c1ccc(C(=O)N(Cc2ncc[nH]2)Cc2ncc[nH]2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 2/20 0.58
HPGD P15428 1/20 0.47
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
THRA P10827 1/20 0.45
THRB P10828 1/20 0.45
NAMPT P43490 7/20 0.44
CHUK O15111 1/20 0.44
INSR P06213 1/20 0.44
MAPK8 P45983 1/20 0.44
CAMKK2 Q96RR4 1/20 0.44
KDM4E B2RXH2 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
TET3 O43151 1/20 0.43
TET2 Q6N021 1/20 0.43
TET1 Q8NFU7 1/20 0.43
GPR4 P46093 1/20 0.43
SIRT2 Q8IXJ6 1/20 0.42
SIRT1 Q96EB6 1/20 0.42
ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1794968 0.91 CXCR4 (0.55) CXCR4HPGDNPC1RAB9ATHRA
SCHEMBL4590045 0.89 CXCR4 (0.64) CXCR4THRBNAMPTALDH1A1
SCHEMBL4589207 0.88 CXCR4 (0.56) CXCR4HPGDNAMPTL3MBTL1ALDH1A1
SCHEMBL4590029 0.88 CXCR4 (0.75) CXCR4NPC1RAB9ATHRATHRB
SCHEMBL1205267 0.86 CXCR4 (0.50) CXCR4HPGDNPC1RAB9ATHRA
SCHEMBL1795606 0.82 CXCR4 (0.49) CXCR4NAMPTL3MBTL1ALDH1A1
SCHEMBL1793506 0.81 CXCR4 (0.48) CXCR4NAMPTL3MBTL1ALDH1A1
SCHEMBL1794515 0.81 CXCR4 (0.49) CXCR4NPC1RAB9AL3MBTL1ALDH1A1
SCHEMBL1792958 0.80 CXCR4 (0.69) CXCR4NAMPT
SCHEMBL1793373 0.80 CXCR4 (0.47) CXCR4NAMPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822459-B2 Compound containing basic group and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2014-09-02 US disclosed
EP-1790639-B1 SPIROCYCLIC COMPOUNDS AND THEIR USE AS CXCR4-ANTAGONISTS ONO PHARMACEUTICAL CO (JP) 2014-03-26 EP disclosed
US-20080009495-A1 Compound Containing Basic Group and Use Thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2008-01-10 US disclosed
EP-1790639-A1 COMPOUND CONTAINING BASIC GROUP AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2007-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009495-A1 Compound Containing Basic Group and Use Thereof CXCR4, CCR5, CXCR3 CXCR4 1/4885HPGD 685/4885NPC1 332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.